WEBULL
WebtradeDownload

Is Bristol Myers Squibb (BMY) A Bargain Following Its Latest Pharmacy Network Update?

Simply Wall St · 1d ago

Onco360 Oncology Pharmacy has been added as a participating pharmacy for Bristol-Myers Squibb (BMY) therapy ZENBEXUS, which is distributed through a restricted ZENBEXUS Risk Evaluation and Mitigation Strategy program for multiple myeloma patients.

Bristol-Myers Squibb shares finished at US$61.15, with the 30-day share price return down 9.11% after a softer 7-day move. However, the 90-day share price return of 10.40% and year-to-date gain of 14.38% point to momentum that has cooled recently rather than reversed.

Compare Bristol-Myers Squibb with other large healthcare companies by reviewing a curated list of solid balance sheet and fundamentals (23 results) for potential ideas in the same arena.

Bristol-Myers Squibb now trades below some analyst targets and at a sizeable intrinsic value discount. After the sharp recent pullback, is that gap a sign of warranted caution, or an opportunity the market is mispricing?

Most Popular Narrative: 8% Undervalued

Against a fair value estimate of $66.21, Bristol-Myers Squibb at $61.15 screens as underpriced in the most followed narrative, with that gap hinging on how the next wave of treatments and cost decisions play out.

Robust late-stage pipeline and ongoing life-cycle management for major brands, together with strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.

See why 224 investors see Bristol-Myers Squibb as 8% undervalued.

Result: Fair Value of $66.21 (UNDERVALUED)

Still, the thesis can break if patent cliffs on key drugs or tougher U.S. pricing rules hit Bristol-Myers Squibb earnings harder than analysts currently model.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Next Steps

Mixed signals like these around Bristol-Myers Squibb can spark debate, so move quickly, review the data in detail, and weigh both the 4 key rewards and 3 important warning signs.

Looking for more Bristol-Myers Squibb investment ideas?

If Bristol-Myers Squibb has you thinking harder about where to put fresh capital, use the Simply Wall St Screener to uncover other focused opportunities before the crowd.

  • Target resilient payouts by reviewing income candidates in the 7 dividend fortresses that combine higher yields with business models built around ongoing distributions.
  • Hunt for mispriced quality across markets through the 30 high quality undervalued stocks, which filters companies with solid fundamentals trading at a discount to estimated worth.
  • Prioritize peace of mind with the 31 resilient stocks with low risk scores, highlighting businesses with sturdier balance sheets and lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.